MergerMay 11, 2026, 04:18 PM
Catalyst Pharma to Merge with Angelini Pharma; Q1 Net Income $63.7M
AI Summary
Catalyst Pharmaceuticals announced a definitive merger agreement with Angelini Pharma S.p.A. on May 6, 2026, under which Catalyst will become a wholly-owned subsidiary of Angelini Pharma. Concurrently, the company reported strong first-quarter 2026 financial results, with net income rising to $63.7 million and total revenues reaching $149.4 million. Product revenues for FIRDAPSE® and AGAMREE® showed significant growth, while FYCOMPA® sales experienced a decline.
Key Highlights
- Merger Agreement with Angelini Pharma S.p.A. announced on May 6, 2026.
- Net income for Q1 2026 increased to $63.7 million from $56.7 million in Q1 2025.
- Diluted EPS rose to $0.50 in Q1 2026 from $0.45 in Q1 2025.
- Total revenues grew to $149.4 million in Q1 2026, up from $141.4 million in Q1 2025.
- Cash and cash equivalents increased to $755.9 million as of March 31, 2026.
- FIRDAPSE® net product revenue increased to $98.9 million in Q1 2026.
- AGAMREE® net product revenue increased to $36.7 million in Q1 2026.
- Repurchased $14.6 million of common stock in Q1 2026.
Price Impact
More from CPRX